Clinic Software← All companies
Sift Biosciences
Proprietary AI-driven discovery platform for T-cell modulating therapies
health AImedtechimmunotherapy
StagePre-seed
Raised$8.4M
Founded2024
Employees5
LocationSan Carlos, CA
Business modelB2B/B2B2C SaaS platform with collaboration/licensing potential (assumed from startup nature; not explicitly stated)
About
Sift Biosciences is a biotechnology company developing an AI-driven platform to discover T-cell modulators derived from bacteria and viruses for treating cancer and autoimmune diseases. The platform combines artificial intelligence, metagenomics, and high-throughput T-cell screening to identify molecules that activate memory T cells and restore immune balance. The company has multiple therapeutic programs in development, including oncology candidates in early clinical stages and autoimmunity programs in active research.
Product
- Value proposition
- AI-driven discovery engine combined with high-throughput cellular screening to identify microbially derived molecules that activate memory T cells and redirect them against cancer and autoimmune targets, enabling durable disease control with safer, targeted immunotherapies.
Founders
- Yue Clare Lou — Co-Founder & CEO
- Maddie Williams — Co-Founder & CTO
Categories
Products
SIFT™ Platformmicrobially derived T-cell modulator discoveryT-cell immunotherapy candidates (preclinical)
Key features
AI-driven discoverymetagenomicshigh-throughput T-cell screeningmicrobially derived moleculesmemory T cell activationimmune balance restoration
Technologies
AI/MLmetagenomicshigh-throughput screeningmicrobial peptide-based therapies
Target conditions
cancerautoimmune diseases
Care settings
clinicalresearchlab
Investors
Freeflow VenturesLifespan Vision VenturesValuence VenturesEisai InnovationSBI US Gateway FundHS Chau Women in Enterprising Science (WIES) ProgramPlug and Play Tech CenterCalifornia Life Sciences FAST Program
News
- Sift Biosciences Announces Oversubscribed $3.7M Pre-seed... · 2026-02-18T00:00:00.000Z
- Sift Biosciences Announces Oversubscribed $3.7M Pre-seed Financing to Advance Next-generation T-cell Immunotherapy Platform | California Life Sciences · 2026-02-18T00:00:00.000Z
- Lifespan Vision Ventures Co-Leads Sift Biosciences’ $3.7M Pre-Seed Financing · 2026-02-18T17:08:45.000Z
- Pillsbury Advises Sift Biosciences on $3.7 Million Oversubscribed Pre-Seed Financing · 2026-02-19T04:57:50.000Z
- Sift Biosciences Raises $3.7M in Pre-Seed Funding · 2026-02-19T09:00:15.000Z
- Sift Biosciences Announces Oversubscribed $3.7M Pre-seed Financing to Advance Next-generation T-cell Immunotherapy Platform - San Francisco Biotechnology Network | Bay Area Life Science News, Jobs & Events · 2026-02-18T18:05:54.000Z
